secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2023-12-18T23:59:59+00:00
Accession:  0000950170-23-070944
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen doses first patient in Phase 1 FREEDOM-DM1 trial; data expected in 2024
------------------------------------------------------------------------------

- First patient dosed in Phase 1 FREEDOM-DM1 trial of PGN-EDODM1 for myotonic dystrophy type 1.
- Safety, transcript splicing correction, and clinical outcome data at 5 mg/kg dose expected in 2024.
- UK MHRA clearance obtained, enabling enrollment in third country (US, Canada, UK).
- Trial to enroll ~24 adults; single ascending doses from 5 to 20 mg/kg with safety-based escalation.
- CEO James McArthur calls dosing a significant milestone toward transformative therapy for DM1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000095017023070944/0000950170-23-070944-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000095017023070944/pepg-20231218.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-070944

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer